Astrazeneca (AZN) EBITDA (2009 - 2026)

Astrazeneca (AZN) has reported EBITDA for 18 consecutive years, with $2.7 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, EBITDA fell 32.6% year-over-year to $2.7 billion; the TTM figure through Mar 2026 stood at $11.6 billion (up 36.71% YoY), while the FY2025 annual figure was $12.9 billion, up 107.27% from the prior year.
• EBITDA came in at $2.7 billion for Q1 2026 at Astrazeneca, down from $2.8 billion in the prior quarter.
• The five-year high for EBITDA was $4.0 billion in Q1 2025, with the low at -$732.0 million in Q2 2022.
• Average EBITDA over 5 years is $1.4 billion, with a median of $1.7 billion recorded in 2022.
• Across the five-year window, EBITDA sank 210.32% in 2024 and jumped 2603.6% in 2025, its largest moves.
• Year by year, EBITDA stood at $1.7 billion in 2022, then climbed by 3.91% to $1.8 billion in 2023, then slumped by 106.24% to -$111.0 million in 2024, then surged by 2603.6% to $2.8 billion in 2025, then dropped by 2.41% to $2.7 billion in 2026.
• According to Business Quant data, EBITDA over the past three periods registered $2.7 billion, $2.8 billion, and $2.6 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.